#Nuclear Medicine Diagnostic (SPECT and PET) market

[aathangmore]

The Global Nuclear Medicine Diagnostic (SPECT and PET) Market (2022-2028) report provides an overview of the development strategies and plans, as well as information regarding the manufacturing cycles and cost structures. Additionally, the report includes import/export utilization, organic market, revenue, and gross margins. The Nuclear Medicine Diagnostic (SPECT and PET) Market Research Report that identifies the leading manufacturers includes GE Healthcare ,Siemens Healthineers ,Philips Healthcare ,Mediso ,Spectrum Dynamics ,Bruker ,SurgicEye ,MIE ,MILabs

In addition, this report offers a quantitative and qualitative analysis of the primary drivers, constraints, opportunities, and challenges influencing the development of the global Nuclear Medicine Diagnostic (SPECT and PET) market. A comprehensive market analysis is provided in the report, together with revenue forecasts for the leading players. In addition, the Nuclear Medicine Diagnostic (SPECT and PET) market report provides information about sales growth in several countries and regions as well as a competitive landscape and specific company analyses. This report examines the prospects and trends of the Nuclear Medicine Diagnostic (SPECT and PET) Market, as well as the current market share, penetration of various kinds, technologies, applications, and geographical regions.

Get Sample PDF Brochure at: https://www.xcellentinsights.com/enquiry/sample/75648

Drivers and restraints of the global Nuclear Medicine Diagnostic (SPECT and PET) market

The report incorporates an analysis of the factors that contribute to the growth of the market. It includes trends, restraints, and drivers that either positively or negatively affect the market. Moreover, this section includes the scope of different segments and applications that may influence the market in the future. Information in this section is based on present trends and historic milestones. As part of this section, the volume of production for each type of product from 2022 to 2028 is also discussed. From 2022 to 2028, this section provides information on the production volume by region. The report contains price analyses for each product type from the year 2022 to 2028, for each manufacturer from 2022 to 2028, for each region from 2022 to 2028, and for the global price from 2022 to 2028.

A thorough assessment of the restraints presented in the report illustrates the contrast with drivers and provides an opportunity for strategic planning. In order to get hold of the lucrative opportunities that are available in the ever-growing market, considering the factors that overshadow the market growth is pivotal. In addition, insights into market experts’ opinions have been taken into consideration to better understand the market.

Inquire more and share questions if any before the purchase on this report at – https://www.xcellentinsights.com/enquiry/buying/75648

Global Nuclear Medicine Diagnostic (SPECT and PET) Market: Segment Analysis

There are specific segments in the research report by region (country), manufacturer, type, and application. Production for each type is provided for the forecast period of 2022 to 2028. In addition, the Consumption by Application segment includes consumption forecasts for the period from 2022 to 2028. It is important to understand the segments in order to identify various factors that contribute to the market’s growth.

A study of the Nuclear Medicine Diagnostic (SPECT and PET) market provides a detailed analysis of the product scope, market overview, opportunities, risks, driving factors, sales, and revenue. The Nuclear Medicine Diagnostic (SPECT and PET) market report also contains information on manufacturers, regions, types, applications, sales channels, distributors, traders, dealers, and research findings. The Nuclear Medicine Diagnostic (SPECT and PET) market report also covers many ups and downs in the market during the Covid-19 pandemic, as well as country or regional factors that have affected the global market.

Nuclear Medicine Diagnostic (SPECT and PET) Market Segments by Type:

SPECT PET

Nuclear Medicine Diagnostic (SPECT and PET) Market Segments by Application:

Oncology Cardiology Neurology Others

Direct Purchase at: https://www.xcellentinsights.com/checkout/75648

This study provides an overview of the Nuclear Medicine Diagnostic (SPECT and PET) market in terms of definitions, classifications, applications, and the industry chain structure. The report provides a comprehensive analysis of the Nuclear Medicine Diagnostic (SPECT and PET) market share in the global market, as well as development trends, competitive landscape analysis, and key regions development status. The development policies and plans as well as manufacturing processes and cost structures are discussed in this paper. Besides import/export consumption and supply and demand data, this report provides cost, price, revenue, and gross margins.

The information provided is derived from current trends and historical milestones. Also included in this section is an analysis of the volume of production on the global market and for each type from 2022 to 2028. The following section addresses the volume of production by region from 2022 to 2028. The report includes an analysis of pricing based on each type from 2022 to 2028, the manufacturer from 2022 to 2028, the region from 2022 to 2028, and the global price from 2022 to 2028.

Reasons to Purchase Nuclear Medicine Diagnostic (SPECT and PET) Market Report

Nuclear Medicine Diagnostic (SPECT and PET) Market Report provides both qualitative and quantitative analysis of the market based on the analysis of market segments involving both economic and noneconomic factors. The report gives an overview of the market value (USD) for each segment and sub-segment within the Nuclear Medicine Diagnostic (SPECT and PET) industry. According to the report, the fastest growing segment and region will dominate the market over the next few years. A geographic analysis of the Nuclear Medicine Diagnostic (SPECT and PET) market, indicating the consumption of the product in each region and the factors that are affecting the market within each region. The competitive landscape includes information about the market rankings of the major companies along with information regarding new services/products, partnerships, business expansions, and acquisitions of the companies profiled in the last five years. Extensive profiles of major market players that include an overview of the company, company insights, and product benchmarking as well as SWOT analyses.

#Nuclear Medicine Diagnostic (SPECT and PET) market #Nuclear Medicine Diagnostic (SPECT and PET) market Size #Nuclear Medicine Diagnostic (SPECT and PET) market Share

[mrfr-blogs]

Evaluating Market Size and Growth Potential in Diagnostic Imaging Market

Market Overview –

The diagnostic imaging market is anticipated to reach USD 49.66 billion by 2032, growing at a CAGR of 4.7% over the forecast period 2023-2032.

The Diagnostic Imaging Market encompasses a wide range of medical imaging technologies used to visualize internal body structures and diagnose various medical conditions. These imaging modalities include X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT).

The diagnostic imaging market is thriving, propelled by advancements in medical imaging technologies. Medical imaging plays a crucial role in disease detection, diagnosis, and treatment planning. With continuous innovation, such as AI integration and portable imaging devices, the market is witnessing sustained growth, meeting the increasing demand for accurate and efficient diagnostic solutions.

In recent years, the diagnostic imaging market has experienced significant growth globally due to several factors. Firstly, there has been increasing demand for diagnostic imaging procedures driven by factors such as aging populations, rising prevalence of chronic diseases, and advancements in imaging technology. Key players in this market include medical device manufacturers, imaging equipment suppliers, healthcare providers, and research institutions, collaborating to develop and commercialize innovative imaging solutions.

Moreover, advancements in imaging technology have led to the development of new imaging modalities with improved resolution, speed, and diagnostic accuracy. These advancements enable earlier detection of diseases, more precise treatment planning, and better monitoring of treatment response, ultimately leading to improved patient outcomes.

Additionally, there is growing interest in personalized imaging approaches tailored to individual patient characteristics, such as genetic profiles, disease stage, and treatment history. Personalized imaging techniques enable healthcare providers to optimize imaging protocols and treatment strategies based on each patient's unique needs, enhancing the efficacy and safety of medical imaging procedures.

Overall, the diagnostic imaging market presents opportunities for growth and innovation as it continues to evolve with advancements in technology and increasing demand for diagnostic imaging services worldwide. Efforts to develop new imaging modalities, improve imaging quality, and expand access to imaging services are essential for advancing healthcare practices and improving patient care.

Market Segmentation –

The global diagnostic imaging market has been segmented on the basis of product, source, and application.

Based on  product type, the market has been divided into x-ray equipment, ultrasound imaging systems, nuclear imaging systems, magnetic resonance imaging (MRI), computed tomography (CT) scanners, and other products

The market, by application, has been segmented into gynecology, oncology, orthopedics, cardiology, gastroenterology, neurology, and other applications

The end-user segment has been further divided into hospitals and clinics, diagnostic centers, research institutes, and others.

Regional Analysis –

Regional analysis of the diagnostic imaging market is essential for understanding the adoption, trends, and dynamics of imaging modalities across different geographic regions. Diagnostic imaging plays a crucial role in healthcare by enabling the visualization of internal body structures for diagnosis, monitoring, and treatment planning. Factors such as healthcare infrastructure, reimbursement policies, and prevalence of diseases influence the demand for various imaging technologies in each region.

Developed regions like North America and Europe often lead in the adoption of advanced imaging modalities such as MRI, CT scans, and PET scans due to well-established healthcare systems, high healthcare spending, and early adoption of innovative medical technologies. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing increasing demand for diagnostic imaging, driven by factors such as rising healthcare expenditure, improving access to healthcare services, and growing prevalence of chronic diseases. Additionally, variations in regulatory frameworks and cultural attitudes towards healthcare impact market dynamics and adoption rates across regions.

Conducting a comprehensive regional analysis enables stakeholders to identify market opportunities, tailor their marketing strategies, and address region-specific challenges such as regulatory compliance and market access. By understanding regional nuances, companies can optimize their market penetration efforts and better serve the diagnostic imaging needs of healthcare providers and patients worldwide.

Key Players –

The Diagnostic imaging company profiles include Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Carestream Health, Esoate SpA, GE Healthcare, Toshiba Medical Systems Corporation, FUJIFILM Holdings Corporation, Siemens Healthcare Private Limited, Hitachi Medical Systems, Hologic Inc., and Shimadzu Corporation.

Related Reports –

Macrolide Antibiotics

Spinal Traction

Performance Enhancing Drugs

Vasectomy

For more information visit at MarketResearchFuture

#Diagnostic Imaging Market #Diagnostic Imaging Market Size #Diagnostic Imaging Market Share #Diagnostic Imaging Market Growth #Diagnostic Imaging Market Trends

[omkarpatel]

Radioactive Tracer Market is Estimated to Witness High Growth Owing to Growing Applications in Medical Diagnostics

Radioactive tracers are radioactive compounds used in medical diagnostics for imaging tissues, organs, bones or blood flow and to detect any defects or health issues. These tracers are tagged with radioactive isotopes and injected or inhaled into the body to enable visualization using imaging modalities like PET and SPECT scans.

Market Dynamics:

The global radioactive tracer market is witnessing high growth owing to increasing applications of nuclear medicine techniques in disease diagnosis and growing geriatric population susceptible to neurodegenerative and cardiovascular diseases. Radioactive tracers find wide usage in positron emission tomography (PET) scans to detect cancer, cardiovascular diseases, and brain disorders by tracking the radioactivity in the body. Furthermore, advancements in imaging technologies and introduction of novel radioactive tracers with improved sensitivity and specificity are also fueling market growth over the forecast period.

Radioactive Tracer Market Drivers:

Increasing Application in Medical Imaging

The rising prevalence of chronic diseases such as cancer, cardiovascular diseases and neurological disorders has fuelled the demand for effective diagnosis. Radioactive tracers play a key role in molecular imaging techniques such as positron emission tomography and single photon emission computed tomography scans which are widely used for diagnosis purposes. Their ability to track biological processes in real time makes them invaluable medical tools. With more people gaining access to healthcare globally and greater emphasis being placed on early detection, the medical imaging sector is set to expand significantly which will drive growth opportunities for radioactive tracers.

Growth in PET Radiopharmaceuticals

within the medical imaging domain, Positron Emission Tomography (PET) is one of the most promising techniques owing to the detailed functional information it provides. PET radiotracers labelled with short-lived radioactive isotopes such as fluorine-18, carbon-11, nitrogen-13 and oxygen-15 are increasingly used for oncological, neurological and cardiac applications. The miniaturization of PET technology along with its combination with other modalities such as CT and MRI has augmented its diagnostic power. All of these factors coupled with favourable reimbursement policies have boosted the demand for PET radiotracers and contributed to the increased production of PET isotopes and tracers.

Radioactive Tracer Market Restrain:

Stringent Regulations

Radioactive tracers are closely regulated by various government agencies due to the risks involved in working with radioactive materials. Manufacturers have to comply with strict guidelines at every stage - right from production and quality testing to transportation and clinical use. Significant investments are required to set up and maintain facilities capable of handling radioisotopes safely and as per regulatory standards. Additionally, the expensive licensing and product approval procedures present obstacles especially for new market entrants. While regulations are necessary to ensure radiation safety, the complexity of the regulatory framework has slowed the pace of innovation and commercialization to some extent in this market.

Radioactive Tracer Market Opportunity:

Theragnostic Applications The convergence of therapeutics and diagnostics, referred to as 'theragnostics', holds tremendous potential for personalized medicine. Radioactive tracers play an important role in theragnostic approaches by enabling imaging-guided drug delivery and monitoring treatment responses in real-time. For instance, radiolabelled nanoparticles, antibodies and peptides can help deliver higher concentrations of therapeutic payloads like chemotherapy drugs directly to tumours while also allowing physicians to visualize drug accumulation and distribution with PET/SPECT. This allows safer, more effective outcomes for conditions such as cancer. Continued advancements in theragnostic radiopharmaceuticals development will open up new opportunities for players in the radioactive tracer market.

Radioactive Tracer Market Trend:

Increasing Demand for Custom Tracers  One of the emerging trends in the radioactive tracer industry is the rising demand for custom radiotracers tailored to specific clinical or research applications. While pre-designed generic radiotracers work well for common indications, customized tracers allow gathering more detailed disease information. Factors such as mutations in molecular targets, rare conditions and personalized medicine approaches require radiopharmaceuticals synthesised from unusual radioisotopes or radiolabelled novel molecular probes. Companies are exploring contract manufacturing models and tracer libraries to facilitate rapid production of user-defined radiotracers. This has prompted wider isotope production along with investments in flexible synthesis platforms and skilled workforce. The custom radiotracer segment will likely be an area of active growth and differentiation in the coming years.

#healt care

[healthcareruhi]

Global Nuclear Medicine Market Size, Trends, Analysis, Growth, Share, Industry Forecast, 2023-2030

Global Nuclear Medicine Market 

The Global Nuclear Medicine Market was valued at US$ 5.97 Bn in 2022 estimated to reach US$ 11.59 Bn by 2030, with a CAGR of 8.33% from 2023-2030. In the field of medicine known as nuclear medicine, numerous ailments such as cancer, cardiac disease, and neurological problems are diagnosed and treated using radioactive materials called radiopharmaceuticals. High-tech cameras allow medical personnel to monitor the radioactive tracers' progress. Additionally, two essential imaging modalities in nuclear medicine are single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Read More: https://qualiketresearch.com/reports-details/Global-Nuclear-Medicine-Market

 Market Drivers

The availability of a strong product pipeline and supportive government programs to increase accessibility to nuclear medicine is anticipated to drive market growth in the coming years. Clinical trials are being conducted on several products, such as betalains, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002. The U.S. has a favorable reimbursement environment for radiopharmaceuticals is expected to stimulate market expansion. In addition, therapy requirements for patients are growing improvements in disease diagnosis and therapy as well as the approval of novel nuclear medicine-based technologies. For instance, GE Healthcare announced in September 2021 the introduction of a unique scanner with a new automated workflow feature that delivers an excellent view of cardiac anatomy and pathology to aid physicians in selecting the best course of treatment for a patient.

 Market Segmentation

The scope of the Global Nuclear Medicine Market covers segmentation based on Diagnostics, Therapeutics, Applications, and Region. Based on Diagnostics, the market is segmented into Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). Based on Therapeutics, the market is classified into Alpha Emitters, Beta Emitters, and Brachytherapy. Based on Applications, the market is bifurcated into Cardiology, Neurology, Oncology, and Other Applications.

Request A Sample: https://qualiketresearch.com/request-sample/Global-Nuclear-Medicine-Market/request-sample

Regional Analysis

The Global Nuclear Medicine Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. The primary market for nuclear medicine is North America.

The United States' booming healthcare industry, rising cancer rates, rising geriatric population, rise in product launches driving up radioisotope usage, and increased initiatives and investments in cutting-edge healthcare solutions for cancer treatment are all expected to contribute to the market's expansion. In the United States, funding for cancer illness research and treatment is likewise rising. The National Centre for Health Statistics (NCHS) of the Centres for Disease Control & Prevention (CDC) has produced data that estimates cancer-related investments might reach up to USD 7,176 million in 2021. 

Key Developments The Department of Nuclear Medicine at PSG Hospitals in Coimbatore, which is outfitted with cutting-edge technology for diagnosing cancer and other disorders, was opened in April 2022 by Health Minister Ma. Subramanian. A program enabling nuclear medicine facilities the chance to become designated and certified Centres of Excellence in Radiopharmaceutical Therapy was introduced by SNMMI in February 2022. Strict regulatory, training, certification, experience, and performance standards will be met by the centers, resulting in optimal patient selection and radiopharmaceutical therapy outcomes. Key Players

Mallinckrodt plc., General Electric Co., Medtronic, plc. (Covidien, acquired by Medtronic), Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group, Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications S.A. 

Key Questions Addressed by the Report • What are the Key Opportunities in Global Bonsai Market? • What will be the growth rate from 2023 to 2030? • Which segment/region will have the highest growth? • What are the factors that will impact/drive the Market? • What is the competitive Landscape in the Industry? • What is the role of key players in the value chain?

About Us:

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers.

QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence.

QualiKet Research strive hard to simplify strategic decisions enabling you to make right choice. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. Our experts provide deep insights which is not available publicly that enables you to take bold steps.

Contact Us:

     6060 N Central Expy #500 TX 75204, U.S.A

     [email protected]

     [phone]

     1201, City Avenue, Shankar Kalat Nagar,

     Wakad, Pune 411057, Maharashtra, India

     [email protected]

     [phone]

     Sharjah Media City , Al Messaned, Sharjah, UAE.

     [email protected]

     [phone]

#Nuclear Medicine Market

[blueweave]

Middle East and Africa Nuclear Imaging Marketsize at USD 285.3 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Middle East and Africa Nuclear Imaging Marketsize to grow at a steady CAGR of 2.68% reaching a value of USD 334.37 million by 2029. Major growth drivers for the Middle East and Africa Nuclear Imaging Market include an increasing prevalence of cancer and cardiac ailments. Nuclear medicine has proven highly effective in treating these diseases, with a notable impact on diagnosis, treatment planning, and treatment response assessment in cancer patients. Factors contributing to the rising cancer burden include an aging population, poor dietary habits, smoking, and physical inactivity. According to GLOBOCAN 2020, both Israel and Saudi Arabia reported a substantial number of new cancer cases. It, in turn, is expected to boost the demand for nuclear medicine imaging, particularly in the Middle East and African region. The magnetic resonance imaging market in this area is forecasted to witness healthy growth. Nuclear medicine's crucial role in diagnosing and managing various diseases is identified as a key growth factor for the market. Also, the Middle East and Africa Nuclear Imaging Market growth is fueled by the adoption of key strategies, such as collaborations and partnerships, by industry players. Hence, such aspects are expected to drive the growth of the Middle East and Africa Nuclear Imaging Market during the forecast period. However, high cost of nuclear imaging equipment and services and lack of skilled nuclear medicine are anticipated to restrain the overall market growth during the period in analysis.

Opportunity - Growing Demand for Hybrid Imaging Systems

Hybrid imaging systems, including PET-CT and SPECT-CT, are experiencing growing acceptance in the Middle East and Africa (MEA) region. The utilization of these systems is on the rise as they integrate functional data from nuclear imaging with anatomical details obtained from CT scans. This integration enhances diagnostic capabilities by providing a more comprehensive and detailed understanding of medical conditions. The increasing adoption of hybrid imaging reflects a trend toward advanced and integrated medical technologies, contributing to improved diagnostic accuracy and patient care in the Middle East and Africa healthcare landscape.

Sample Request @ https://www.blueweaveconsulting.com/report/middle-east-and-africa-nuclear-imaging-market/report-sample

#Blueweave #consulting #marketresearch #marketforecast #medicaldevices

[neha24blog]

Nuclear Medicine Market Segment Analysis By Product, Application, End-Use, Region And Forecast Till 2030: Grand View Research Inc.

San Francisco, 17 Nov 2023: The Report Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030 The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the…

View On WordPress

#Nuclear Medicine Industry #Nuclear Medicine Market #Nuclear Medicine Market 2023 #Nuclear Medicine Market 2030 #Nuclear Medicine Market Revenue #Nuclear Medicine Market Share #Nuclear Medicine Market Size

[vanshika393]

Medical Imaging Equipment Market Size Expected To Acquire USD 48,786.03 million By 2030 At CAGR of 5.60%

The latest market report published by Credence Research, Inc. “Global Medical Imaging Equipment Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2030. The market for medical imaging equipment has been expanding steadily in recent years, and between 2023 and 2030, it is anticipated to rise at a CAGR of 5.60%. The market was estimated to be worth USD 31,548.9 million in 2022, and it is anticipated to be worth USD 48,786.03 million in 2030.

Medical Imaging Equipment Market Overview:

The Medical Imaging Equipment Market refers to the global industry that produces and sells various devices used to create visual representations of the interior of a body for clinical analysis and medical intervention. These devices play a crucial role in diagnosing, monitoring, and treating various medical conditions by providing valuable insights into the structure and functioning of internal organs and tissues. The market includes a wide range of imaging modalities, each with its own technology and applications.

Types of Medical Imaging Equipment:

Computed Tomography (CT) Scanners: CT scanners use a series of X-ray images taken from different angles to create detailed cross-sectional images of the body. They are especially useful for visualizing internal structures in 3D.

Magnetic Resonance Imaging (MRI) Systems: MRI uses strong magnetic fields and radio waves to generate detailed images of soft tissues, organs, and the nervous system. It's particularly valuable for diagnosing neurological and musculoskeletal conditions.

Ultrasound Machines: Ultrasound imaging uses high-frequency sound waves to create images of internal structures. It's commonly used for monitoring pregnancies, examining organs, and guiding procedures.

Nuclear Medicine Equipment: This category includes equipment like Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners. These technologies use radioactive tracers to visualize organ function and metabolism.

Partnerships and Collaborations:

Siemens Healthineers and Novartis: Siemens Healthineers entered into a partnership with Novartis to develop and commercialize assays measuring blood levels of certain therapeutic drugs using Siemens' Atellica Solution immunoassay analyzer. This collaboration aimed to enhance personalized treatment and monitoring of patients.

Philips and B. Braun Melsungen: Philips and B. Braun Melsungen collaborated in 2020 to provide an integrated regional solution for continuous ultrasound-guided regional anesthesia. The collaboration aimed to improve patient care during surgery by combining B. Braun's regional anesthesia expertise with Philips' ultrasound technology.

GE Healthcare and Roche: GE Healthcare and Roche collaborated in 2020 to develop and market digital diagnostics solutions, combining Roche's expertise in in-vitro diagnostics with GE Healthcare's expertise in medical imaging and monitoring.

Acquisitions:

Philips Acquires BioTelemetry: Philips acquired BioTelemetry, a company specializing in remote cardiac diagnostics and monitoring. This acquisition aimed to expand Philips' remote patient monitoring offerings and enhance its digital healthcare solutions.

Siemens Healthineers Acquires Varian Medical Systems: Siemens Healthineers completed the acquisition of Varian Medical Systems, a company known for its advanced radiation therapy solutions for cancer treatment. This acquisition aimed to strengthen Siemens Healthineers' oncology portfolio.

Canon Medical Systems Acquires Delft Imaging Systems: Canon Medical Systems acquired Delft Imaging Systems, a company focused on providing medical imaging solutions for low-resource settings. This acquisition aimed to enhance Canon's efforts to provide healthcare solutions to underserved regions.

Browse 240 pages report By End-User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Ambulatory Care Centers) By Technology (Digital Imaging, Analog Imaging, 3D and 4D Imaging, Portable and Point-of-Care Imaging) By Specialty and Advanced Features Contrast-Enhanced Imaging, Functional Imaging, Interventional Imaging, Molecular Imaging) Growth, Future Prospects & Competitive Analysis, 2016 – 2030 -  https://www.credenceresearch.com/report/medical-imaging-equipment-market

Here are some of the significant growth factors:

Technological Advancements: Continuous advancements in medical imaging technology, such as MRI, CT scans, ultrasound, and X-ray systems, have played a pivotal role in market growth. Improved imaging quality, faster scans, and reduced radiation exposure have expanded the applications and adoption of these technologies.

Aging Population: The global population is aging, leading to an increased demand for medical imaging services. As people age, they are more likely to require medical imaging for diagnostic purposes and disease management.

Rising Chronic Diseases: The prevalence of chronic diseases such as cancer, cardiovascular diseases, and orthopedic conditions is on the rise. These conditions often require diagnostic imaging for accurate diagnosis and treatment planning.

Emerging Markets: Developing countries are expanding their healthcare infrastructure, increasing access to medical imaging services. This has led to a significant market growth in regions like Asia-Pacific, Latin America, and the Middle East.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Medical Imaging Equipment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Medical Imaging Equipment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/medical-imaging-equipment-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/ambulatory-surgery-centers-market

https://www.credenceresearch.com/report/veterinary-surgical-sutures-market

Browse Our Blog: https://www.linkedin.com/pulse/medical-imaging-equipment-market-grow-steadily-over-cagr-shukla

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

#helathcare

[distinguishedhideoutdestiny]

Global Diagnostic Radiopharmaceuticals and Contrast Media Market Is Estimated To Witness High Growth Owing To Rising Demand for Accurate Diagnosis and Imaging Techniques

The global Diagnostic Radiopharmaceuticals and Contrast Media Market is estimated to be valued at US$ 6,811.4 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. A) Market Overview: Diagnostic radiopharmaceuticals and contrast media are substances that are used during medical imaging procedures to provide enhanced images of internal organs and structures of the body. These products play a vital role in accurate diagnosis and help physicians to detect diseases such as cancer, cardiovascular disorders, and neurological conditions. They are commonly used in procedures such as X-ray, CT scan, MRI, and nuclear medicine imaging. The need for diagnostic radiopharmaceuticals and contrast media arises from the increasing prevalence of chronic diseases, growing geriatric population, and advancements in medical imaging technologies. These products help in improving the quality of diagnostic images by enhancing the contrast between different tissues and highlighting abnormal areas for accurate diagnosis. The rise in awareness about early disease detection and screening programs also contributes to the market growth. B) Market Key Trends: One key trend in the Diagnostic Radiopharmaceuticals and Contrast Media Market is the growing preference for personalized medicine. With advancements in medical imaging technologies, healthcare providers are shifting towards personalized treatment plans based on individual patient needs. This trend has led to the development of specialized diagnostic radiopharmaceuticals and contrast media that can target specific diseases or conditions. For example, radioactive tracers are commonly used in nuclear medicine imaging to detect specific diseases or conditions by targeting specific organs or tissues. C) PEST Analysis: Political: Governments across the globe are increasing their focus on improving healthcare infrastructure and promoting early disease detection. This creates a favorable political environment for the growth of the diagnostic radiopharmaceuticals and contrast media market. Economic: The market is driven by factors such as increasing healthcare expenditure and growing demand for advanced medical imaging technologies. The high cost associated with the development and manufacturing of these products may pose a challenge to market growth. Social: The rising prevalence of chronic diseases, growing aging population, and increasing awareness about early disease detection and screening programs are driving the demand for diagnostic radiopharmaceuticals and contrast media. Technological: Advancements in medical imaging technologies, such as PET-CT and SPECT-CT, are driving the demand for diagnostic radiopharmaceuticals and contrast media. These technologies provide high-resolution images and improved diagnostic accuracy. D) Key Takeaways: - The global Diagnostic Radiopharmaceuticals and Contrast Media Market is expected to witness high growth, exhibiting a CAGR of 5.8% over the forecast period. This growth can be attributed to the increasing demand for accurate diagnosis and imaging techniques. - North America is expected to dominate the market, owing to the presence of advanced healthcare infrastructure and increasing adoption of medical imaging technologies. - Siemens Healthineers, Nordion Inc., Lantheus Holdings Inc., Guerbet Group, GE Healthcare, Curium, Bracco Imaging SpA, Bayer AG, Cardinal Health Inc., and NTP Radioisotopes SOC Ltd. are some of the key players operating in the global Diagnostic Radiopharmaceuticals and Contrast Media Market.

#Diagnostic Radiopharmaceuticals and Contrast Media Market

[ellinapark]

Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2028

The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market. What’s keeping:

Cardinal Health (United States)

GE Healthcare (United States)

Curium (France)

Lantheus Medical Imaging (United States)

Bayer AG (Germany)

Bracco Imaging (Italy)

Eczacýbaþý-Monrol Nuclear Products (Turkey)

 Nordion (Canada)

Advanced Accelerator Applications (France)

NTP Radioisotopes (South Africa)

Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.

The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360

On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa. What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99

Market Challenges: Hospital budget cuts and high equipment costs

Market Opportunities: Use of radiopharmaceuticals in neurological applications

Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions

Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments

Presented By

AMA Research & Media LLP

[delvenservices]

Nuclear Medicine/Radiopharmaceuticals Market – Trends Forecast Till 2028

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology), Procedures and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

The Nuclear Medicine/Radiopharmaceuticals Market size is projected to reach a CAGR of 10.1% from 2021 to 2028.

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.

Increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99 are some of the factors that have supported long-term expansion for Nuclear Medicine/Radiopharmaceuticals Market.

Request For Free Sample Report: https://www.delvens.com/get-free-sample/radiopharmaceuticals-market-trends-forecast-till-2028

Regional Analysis

North America is expected to account for the largest share of the nuclear medicine market during the forecast period, The large share of North America can be attributed to the development of novel technologies for radioisotope production, government funding, increasing R&D expenditure and company initiatives in the region.

Key Players

Mallinckrodt plc.

General Electric Co. (healthcare division)

Medtronic, Inc.

Bayer AG

Cardinal Health, Inc.

Lantheus Medical Imaging, Inc.

IBA Group

Make an Inquiry Before the Purchase: https://www.delvens.com/Inquire-before-buying/radiopharmaceuticals-market-trends-forecast-till-2028

Recent Developments

In 2021, Bracco entered into a partnership with CardioNavix which will help improve patient access to cardiac PET imaging.

In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Nuclear Medicine/Radiopharmaceuticals Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Purchase This Report At: https://www.delvens.com/checkout/radiopharmaceuticals-market-trends-forecast-till-2028

Report Scope

Nuclear Medicine/Radiopharmaceuticals Market is segmented into type, application, procedural volume assessment and region.

On the basis of Type

Diagnostic Nuclear Medicine

Therapeutic Nuclear Medicine

Brachytherapy Isotopes                        

On the basis of Application

Diagnostic Applications

On the basis of Procedural Volume Assessment   

Diagnostic Procedures

Therapeutic Procedures

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

[phone]

[email protected]

[vicky8588]

Radiopharmaceuticals Market

The “Radiopharmaceuticals Market” size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2023 to 2030. Radiopharmaceuticals are a class of pharmaceutical medicines with a significant radioactivity level. Radiopharmaceuticals are pharmaceuticals formulations that contain radioactive isotopes. These medications can be administered intravenously, orally, or interstitially. In addition, compared to X-rays and other external radiation imaging systems, it is a suitable and secure alternative for patients and aids physicians in diagnosis.

Radiopharmaceuticals and nuclear medicine are increasingly utilized in diagnostic imaging and radiotherapy. This has paved the way for the market expansion of radiopharmaceuticals. Nuclear medicine and radiopharmaceuticals aid in diagnosing organs affected by any pathological condition, particularly malignancy. This modality's applications have expanded from oncology to cardiology, neurology, and infection detection due to the rapid development of nuclear imaging technologies, particularly PET/PET-CT.

To Get a Free Sample Click here

Radiopharmaceuticals Market Dynamics:

Drivers:

The radiopharmaceuticals market is driven by several factors, including:

Increasing prevalence of cancer: With the rising incidence of cancer, the demand for radiopharmaceuticals is increasing as they are used in cancer diagnosis, staging, and treatment.

Growing demand for nuclear medicine: Radiopharmaceuticals are an essential part of nuclear medicine, which is increasingly being used for the diagnosis and treatment of various diseases.

Technological advancements in imaging modalities: The development of new imaging modalities, such as PET/CT and SPECT/CT, is driving the demand for radiopharmaceuticals, as these modalities require the use of radiopharmaceuticals.

Favorable regulatory policies: Governments are implementing favorable policies and regulations to promote the use of radiopharmaceuticals in healthcare, which is driving the growth of the market.

Increasing investment in research and development: Pharmaceutical companies are investing heavily in research and development to develop new radiopharmaceuticals and improve the existing ones, which is driving the growth of the market.

Rising geriatric population: With the increasing geriatric population, the incidence of chronic diseases is on the rise, which is driving the demand for radiopharmaceuticals in diagnosis and treatment.

Growing awareness about the benefits of nuclear medicine: As the awareness about the benefits of nuclear medicine and radiopharmaceuticals is increasing among patients and healthcare professionals, the demand for these products is also increasing.

Restraints:

Side-Effects of Radiopharmaceuticals

Numerous adverse effects of radiopharmaceuticals inhibit market expansion. Among the side effects are chills, severe lethargy, difficulty breathing, flushing or redness of the skin, nausea or vomiting, skin rash, hives, itching, severe headache, and abdominal pain. Therefore, these factors inhibit market expansion.

This radiopharmaceuticals market report provides details of new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographies served, and competitive landscape. For more information on the radiopharmaceuticals market, contact Data Bridge Market Research for an Analyst Brief; our team will assist you in making well-informed decisions for market expansion.

Opportunities:

Increasing Demand for Nuclear Imaging Technologies

The development of nuclear imaging technologies, such as PET or PET-CT, has aided in expanding the applications of this modality from oncology to cardiology, neurology, and infection detection. These technological advances have significantly increased the number of PET and SPECT procedures. In the United States, approximately 2,220,300 PET treatments were performed in 2020, up from 2,200,800 in 2019. Consequently, it is anticipated that this factor will increase radiopharmaceutical market revenue.

Growing R&D Activities Associated with Radiopharmaceuticals

Increased radiopharmaceutical-related R&D activities enhanced market growth. In 2022, for example, the first patient dosed in phase III clinical trials for PET radiopharmaceutical imaging agents developed by GE Healthcare was initiated. The strategic approach will help to enhance patient care by identifying adult Parkinson's disease with greater precision. GE Healthcare will expand its radiation patent portfolio. Thus, this factor stimulates market expansion.

Market Segmentation Analysis:

The global Radiopharmaceuticals Market” is Segmented by Radioisotopes, Application, Source, End-user, and Region.

By Radioisotopes

Tec.99 

F18 

Iodine 131 

Lutetium 177

Yttrium 90 

Gallium 68 

Gallium 67 

Rubidium 82 

Iodine 123 

Iodine 125 

Indium 111 

Others

By Application

Oncology 

Cardiology

Gastroenterology 

Neuroendocrinology 

Neurology

Nephrology 

Others

By Source 

Cyclotrons

Nuclear Reactor

By End User

Hospitals 

Diagnostic Imaging Centers 

Ambulatory Surgical Centers

Cancer Research Institute

By Region:

North America 

Latin America 

Europe 

Asia Pacific 

Middle East, and Africa

Competitive Landscape:

The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are 

Siemens AG

Positron Corporation

Curium

GE Healthcare

Lantheus Holdings Inc.

Sotera Health LLC

Bayer AG

Eckert & Ziegler

Novartis AG, and BWX Technologies Inc. 

The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.

Siemens AG

Siemens is a technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power.

Recent Development

In 2021, NorthStar Medical Radioisotopes, LLC, a global radiopharmaceutical developer, and GE Healthcare confirmed an exclusive partnership to manufacture and distribute iodine-123 (I-123) capsules in the U.S. The product will assist GE Healthcare in enhancing its product portfolio and boosting its market position.

In 2021, Noria Therapeutics Inc. and PSMA Pharmaceuticals Inc. were acquired by Bayer AG Targeted both radiotherapy businesses are developing therapeutic and diagnostic radiopharmaceuticals. The acquisition is anticipated to add to Bayer's current nuclear medicine oncology portfolio.

Regional Analysis:

North America dominates the radiopharmaceuticals market because of the huge base of healthcare facilities and increasing overweight population base. Also, wide presence of a huge patient population suffering from chronic diseases such as coronary disorders, cancer, and strokes and rising number of research activities in this region are also boosting the market growth.       

Asia-Pacific is expected to witness significant growth due to the growth in government initiatives to raise awareness and increasing research activities in the region. Also, growing availability of the well-established infrastructure, wide presence of major market players, growth in cases of cardiovascular diseases are boosting the growth rate of the market.

About DataM Intelligence:

DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to clients' needs in crucial business areas. DataM Intelligence has an online platform covering industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages, among others. Our forum has Insights on markets that uncover the latest market research data distinct from the competition. With coverage across ten major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the Market by providing a complete view of the Market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates ease access and custom personalization to research and markets.

Contact Us:

For more information: Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: [phone]

Website: www.datamintelligence.com

#Radiopharmaceuticals Market #Radiopharmaceuticals

[researchvishal]

Radiopharmaceuticals Market To Undertake Strapping Growth By The End 2032 | FMI

The global radiopharmaceuticals market stands at US$ 6.2 Bn as of now and is expected to reach US$ 9.5 Bn by the year 2032 at a CAGR of 4.3% between 2022 and 2032.

Radiopharmaceuticals imply medications containing radioisotopes that could be used as both – therapeutic agents and diagnosis medications. Radiopharmaceuticals manage critical as well as chronic diseases. These days, various diagnostics are aimed towards organs with nuclear medicine radiopharmaceuticals.

PET and SPECT techniques are used in abundance while deploying radiopharmaceuticals. Some of the distinct features of radiopharmaceuticals include non-invasiveness, cost-effectiveness, easy of diagnosis, and higher sensitivity. Clinical applications include cardiology, oncology, lymphoma, and tumor.

Growing awareness regarding positive results provided by radiopharmaceuticals in checking chronic illness is one of the catalysts to radiopharmaceuticals market.

On the other hand, the fact that radiopharmaceuticals have half-life could restrain the market. It’s a known fact that radiopharmaceuticals involve higher investment. Short expectancy or half-life is one of the crucial factors restricting demand for radiopharmaceuticals. Thus, it’s only the developed regions who are able to increasingly adopt radiopharmaceuticals as of now. The developing economies still need to incorporate the technology to the fullest. Future Market Insights has walked through these functionalities with future prospects in its latest market study entitled ‘Radiopharmaceuticals Market’.

Key Takeaways from Radiopharmaceuticals Market

North America dominates the radiopharmaceuticals market due to rising frequency of cardiovascular diseases and cancer and the scenario is expected to persist even in the forecast period. Adopting innovative radioisotope production methods for treating chronic disorders is another reason.

Europe, led by the UK, is also expected to hold a significant market share due to the UK being subject to maximum incidences of cancer. Cancer Research UK estimate says that the UK alone houses 367,167 cancer patients.

The Asia-Pacific is poised to grow blatantly in the forecast period with it witnessing new product launches, collaborations, distribution agreements, acquisitions in an aplomb.

“The fact that radiopharmaceuticals are broadly used as biomarkers in molecular imaging is expected to take the radiopharmaceuticals market by storm in the upcoming period”, says an analyst from Future Market Insights.

Competitive Landscape

GE Healthcare inked an agreement with NorthStar Medical Radioisotopes, LLC for producing and distributing iodine-123 (I-123) capsules all across the US.

Bracco Diagnostics Inc., in March 2021, entered into partnership with CardioNavix, LLC for enhancing patients’ access to cardiac PET imaging. The new program is termed as ‘Bracco Mobile Isotope Service’, which ought to facilitate better patient care sites for providing cardiac PET imaging.

Jubilant Radiopharma, in August 2020, signed a MoU (Memorandum of Understanding) with Navidea Biopharmaceuticals, which focuses on an ELDA (Exclusive License and Distribution Agreement) for the latter’s diagnostic imaging agent called ‘Tilmanocept (technetium Tc 99m tilmanocept injection) in LATAM, Mexico, Canada, and the US.

Bayer AG, in June 2021, announced that it would acquire Noria Therapeutics Inc. along with PSMA Therapeutics Inc. with the objective of widening the former’s oncology portfolio that is into existence.

Norgine B.V., in March 2020, completed the acquisition of Azanta A/S, a specialty biopharmaceutical company. This included Nimorazole, a hypoxic radiosensitizer to treat cancer, and Angusta to facilitate labor induction.

Curium, in the year 2019, completed acquisition of MAP Medical, which would actually help it in strengthening the footprint all over the Europe with access to Baltic and Nordic countries.

The US FDA, in December 2020, completed approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11). It holds the distinction of being the very first drug for PET imaging for diagnosing prostate cancer.

Top Radiopharmaceuticals companies : Siemens AG,Positron Corporation,Novartis (Advanced Accelerator Applications),Curium,GE Healthcare,Lantheus Holdings Inc.,Sotera Health LLC (Nordion Inc.),Bayer AG,Eckert & Ziegler,

Key Segments Covered in the Radiopharmaceuticals Industry Analysis

Radiopharmaceuticals Market by Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

Radiopharmaceuticals Market by Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

Radiopharmaceuticals Market by Source:

Cyclotrons

Nuclear Reactors

Radiopharmaceuticals Market by End User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

[omkarpatel]

Radiopharmaceuticals in Nuclear Medicine Market is Estimated to Witness High Growth Owing to Demand for PET Imaging in Oncology

Radiopharmaceuticals are radioactive compounds that are used for diagnosis and treatment of various diseases. They emit radiation and help in imaging various body parts in medical procedures such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Radiopharmaceuticals find major applications in diagnosis and treatment of cancer, heart diseases, neurological disorders, and other abnormalities.

The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$6,700.05 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The increasing incidence of cancer and cardiovascular diseases has significantly driven the demand for PET imaging globally. Positron emission tomography (PET) uses radiopharmaceuticals to produce three-dimensional images of functional processes in the body. It plays a vital role in diagnosing, staging, and restaging of various cancers. According to the International Agency for Research on Cancer (IARC), cancer burden worldwide is projected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. PET imaging provides accurate diagnosis and helps in effective cancer treatment planning. This growing cancer burden presents lucrative opportunities for growth of radiopharmaceuticals used in PET scans. Development of new radiotracers for disease diagnostics using PET imaging technique will further support the demand for radiopharmaceuticals over the forecast period. Porter's Analysis Threat of new entrants: Low capital requirement and established distribution channels lower barriers to entry. However, stringent regulatory approvals and need for specialized infrastructure and human resources pose significantentry barriers. Bargaining power of buyers: Large pool of suppliers and differential product offerings empowers buyers. Switching costs are low. Bargaining power of suppliers: Specialized product expertise and compliance requirements grant suppliers a differentiated position of strength in negotiations. Threat of new substitutes: Alternate diagnostic techniques pose substitutive threats but limited success so far due to advantages of nuclear medicine diagnostics. Competitive rivalry: Intense competition due to low differentiation and prominence of few global leaders. Collaboration and acquisitionare common competitive strategies. SWOT Analysis Strengths: Non-invasive diagnostic technique. High diagnostic accuracy. Wide application scope across disease areas. Weaknesses: High infrastructure and skilled workforce requirements. Limited product differentiation. Supply chain vulnerabilities. Opportunities: Emerging theranostics applications. Personalized medicine trends. Aging demographics driving disease prevalence. Threats: Stringent regulations. Reimbursement reimbursement uncertainties. Substitutive diagnostic technologies. Key Takeaways The global radiopharmaceuticals in nuclear medicine market is expected to witness high growth over the forecast period. Key regional markets include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The Asia Pacific region is expected to be the fastest growing market owing to increasing healthcare investments, rising disease incidence, and growing adoption of nuclear medicine diagnostics. Key players operating in the radiopharmaceuticals in nuclear medicine market include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.

#healthcare

[adityarana1687-blog]

Coronary Heart Disease Diagnostic Imaging Devices Market Predicted To Surpass $2.96 Billion By 2030

The global coronary heart disease diagnostic imaging devices market is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.9% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.

Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.

The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively. However, diabetic and hypertensive patients witnessed a severe risk of CVD ultimately leading to death. Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.

Request a free sample copy or view report summary: Coronary Heart Disease Diagnostic Imaging Devices Market Report

Coronary Heart Disease Imaging Devices Market Report Highlights

Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.

Computed tomography held the highest CAGR of 7.6% due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.

Asia Pacific is anticipated to be growing at the fastest CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.

Coronary Heart Disease Imaging Devices Market Segmentation

Grand View Research has segmented the global coronary heart disease imaging devices market based on modality and region:

Modality Outlook (Revenue, USD Million,2018 - 2030)

Computed Tomography

X rays

Ultrasound

Magnetic Resonance Imaging

Nuclear Medicine

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

U.K.

Germany

France

Italy

Spain

Norway

Denmark

Netherlands

Poland

Austria

Switzerland

Japan

China

India

South Korea

Brazil

Mexico

Argentina

South Africa

Saudi Arabia

UAE

List of Key Players in Coronary Heart Disease Imaging Devices Market

GE

Fujifilm

Siemens

Toshiba

Hitachi

Koninklijke Phillips

Canon Medical Systems Corporation

Analogic Corp

#Coronary Heart Disease Diagnostic Imaging Devices Market

[blueweave]

Europe Nuclear Medicine Marketsize at USD 1.75 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Europe Nuclear Medicine Marketsize to grow at a robust CAGR of 12.03% reaching a value of USD 3.46 billion by 2029. Major growth drivers for the Europe Nuclear Medicine Marketinclude the growing prevalence of cancer and cardiac diseases and increasing applications of SPECT and PET. The surge in the prevalence of cardiac ailments and cancer stands as the pivotal driver for the demand within the European nuclear medicine market. According to the British Heart Foundation England Factsheet from August 2022, approximately 7.6 million individuals in the United Kingdom are living with heart or circulatory diseases. This source further projects that over half of the population in the United Kingdom will experience a heart or circulatory condition in their lifetime. Notably, the prevalence of heart and circulatory diseases surpasses that of cancer and Alzheimer's disease combined, with an estimated 48,000 individuals under the age of 75 years succumbing to heart and circulatory diseases annually. Consequently, the escalating burden of cardiovascular diseases is expected to boost the market demand for nuclear medicine, particularly in diagnosing, assessing, and evaluating coronary artery diseases, cardiomyopathy, and potential heart damage from chemotherapy or radiotherapy, thereby fostering market growth. Also, Macmillan Cancer Support's October 2022 data reveals 3 million people with cancer in the UK, expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This rising cancer prevalence is expected to boost the demand for nuclear medicine, aiding tumor detection and treatment, fostering market growth. However, high cost of nuclear medicine equipment and services and reimbursement challenges are anticipated to restrain the overall market growth during the forecast period.

Opportunity - Increasing Adoption of Nuclear Medicine across Europe

The expansion of nuclear medicine services into rural areas presents a significant opportunity for the growth of the Europe Nuclear Medicine Market. By extending the reach of nuclear medicine facilities to less urbanized regions, there is the potential to enhance accessibility to advanced diagnostic and therapeutic services, addressing healthcare disparities and contributing to early disease detection and treatment in rural populations. This increased availability of nuclear medicine technologies in rural areas aligns with the broader goal of improving healthcare infrastructure and outcomes across Europe, fostering a positive market outlook in the region.

Sample Request @ https://www.blueweaveconsulting.com/report/europe-nuclear-medicine-market/report-sample

#Blueweave #Consulting #marketreserch #marketforecast #marketshare

[fmihealthcareresearch]

Molecular Imaging Market Size, Global Industry Manufacturers, Share and Forecasts 2031

Molecular imaging is an emerging diagnostic technology that allows visualization, differentiation, and quantify various biological processes occurring inside a living organism at the molecular and cellular level. The global molecular imaging market is estimated to be valued approximately at US$ 4 Bn in 2021, finds Future Market Insights (FMI) in a study.

Molecular imaging targets molecular pathways and mechanisms associated with a particular disease present inside a living body. It enables to study of the molecular abnormalities taking place inside the body to carry out early detection of disease and to optimize medications aiming for disease-related molecular targets. Nuclear medicine plays a vital role in conducting a molecular imaging process and can be broadly used for the treatment of distinct cancer and related diseases.

Clinical molecular imaging is trending towards hybrid modalities such as PET-CT, SPECT, or PET-MR that provide high-resolution anatomical imaging. PET-CT is anticipated to gain maximum revenue share over the forecast period, and the segment is projected to expand at a CAGR of 16.3% during the forecast period.

Molecular imaging has evolved as a promising tool for early detection of cancers and cardiac diseases, providing a more complete picture of the tumor genome, as well as monitoring tumor emergence during disease. Molecular imaging provides the ability to accurately evaluate biological responses to the treatment of individual patients over time, opening the door to personalized medical techniques directed by molecular imaging reporters.

Key Takeaways from Molecular Imaging Market Study

Molecular imaging market will register accelerating demand, enabling a y-o-y growth of nearly 11% in 2021

Backed by presence of a state-of-the-art healthcare infrastructure, the U.S. accounts for nearly 65% sales in North America

Driven by rising cases of cancer, the U.K. market will exhibit above 14% y-o-y growth in 2021

Government initiatives aimed at offering advanced medical care will enable growth in Germany and France

The market in China is expected to surge at a CAGR of over 10% from 2021 to 2031

 “Increasing research & development activities in cancer-specific drug discovery and other chronic diseases are expected to boost demand for molecular imaging. Besides this, as a result of increasing incidence of cancer the demand for highly sensitive and precise diagnostic for better treatment solutions is increasing,” says a Future Market Insights analyst.

Molecular Imaging Needs Rising In Response to Increasing Cancer Cases According to the World Health Organization (WHO) in 2020, breast cancer emerged as the most common type of cancer, affecting 2.2 million people around the world.  Lung cancer has been the leading cause of death with over 1.7 Mn of total deaths in 2020. North America has the highest incidence rate of cancer followed by East Asia. This rise in the cancer population is leading to a rise in the demand for diagnostic imaging, thereby catalyzing the demand for molecular imaging.

Who is Winning? Key players in the molecular imaging market are keenly focusing on carrying out strategic activities such as acquisitions, collaborations, and mergers, product launch, global expansion to create a strong position in the market is leading to vigorous developments which are helping the market to grow at a considerable rate.

For instance, in 2019, Bruker Corporation launched a benchtop magnetic resonance spectrometer with a high-field 9.4 Tesla small animal MRI system with integrated in-line PET. Thus strengthening its product portfolio.

Strategies adopted by key players are often intended at global expansion. They largely  focus on product launches and mergers & acquisitions. There have been a few strategic partnerships among leading players to enhance the product line and better facilities for end-user.

In September 2020, Bruker Corporation announced the acquisition of Canopy Biosciences, LLC. This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques.

Some of the key players are Key market players covered by Future Market Insights in the report are is Hermes Medical Solutions, Bruker Corporation, GE Company,  Fujifilm Holdings Corp.,  Koninklijke Philips N.V.,  Siemens AG,  Toshiba Medical System Corp.,  Mirada Medical Limited,  Carestream Health, Inc.,  Esaote SpA, Positron Corporation,  Medisco Ltd.,  Hitachi Medical Corp.,  MIM Software Inc.

Want more insights? Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global molecular imaging market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights based on a modality (Positron Emission Tomography (PET), Positron Emission Tomography- Computed Tomography (PET-CT), Positron Emission Tomography- Magnetic Resonance (PET-MR), Single Photon Emission Computed Tomography (SPECT), Software, Magnetic Resonance Spectroscopy, Molecular Ultrasound Imaging), Application (Cardiology, Oncology, Gastrointestinal Disorders, Neurology Disorders, Others) and end-user ( Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers), across seven major regions of the world.

Molecular Imaging Market by Category Modality

Positron Emission Tomography (PET)

Positron Emission Tomography- Computed Tomography (PET-CT)

Positron Emission Tomography- Magnetic Resonance (PET-MR)

Single Photon Emission Computed Tomography (SPECT)

Software

On Premises Solutions

Cloud Based Solutions

Magnetic Resonance

Molecular Ultrasound Imaging

Application

Cardiology

Oncology

Gastrointestinal Disorders

Neurology Disorders

Others

 End User

Hospitals

500+ Beds

200-499 Beds

Less than 200 Beds

Ambulatory Surgical Centres

Diagnostic Centres

Information Source:

#Molecular Imaging Market